Phenex Pharmaceuticals AG, founded in 2002, is a privately held drug discovery company based in the Biotech Cluster Rhine-Neckar located in the southwest of Germany with laboratories & offices in Ludwigshafen & Heidelberg. The company focuses on small-molecule drug discovery with nuclear receptors.
Nuclear receptors are of major importance for the body's homeostasis, as they integrate different intra- and extracellular signalling to initiate and regulate gene expression programs. This key role in a wide variety of signalling pathways qualifies them as important pharmacological targets. Nuclear receptor modulating drugs account for about 10% revenues of the total ethical drug market, applied in different indications, such as Hormone Replacement Therapy, Women's Health, Inflammation, Diabetes, Cancer and Dermatology.
Proprietary Drug Discovery Programs
We aim to utilize our special nuclear receptor know how & technology platform to develop novel innovative therapies for diseases with a high unmet medical need and a significant market potential. Our business goal is to partner these programs for further clinical development after preclinical and clinical proof-of-concept studies.
Discovery Services on Nuclear Receptors
In addition to its own drug discovery projects Phenex also offers its resources and capabilities in the field of nuclear receptors to customers in the pharmaceutical and other Life Science industries under its business unit Discovery Services. The service business model ranges from contract screening services up to integrated research collaborations. You will find in Phenex a reliable partner for nuclear receptor drug discovery. Our references encompass more than 70 international pharmaceutical and biotechnology companies, veterinary medicine and food companies in Europe, Japan and North America.